The heterotrimeric mTORC1 protein kinase nucleates a signaling network that promotes cell growth in response to insulin and becomes constitutively active in cells missing the TSC1 or TSC2 tumor suppressors. Insulin stimulates the phosphorylation of S6K1, an mTORC1 substrate, but it is not known how mTORC1 kinase activity is regulated. We identify PRAS40 as a raptor-interacting protein that binds to mTORC1 in insulin-deprived cells and whose in vitro interaction with mTORC1 is disrupted by high salt concentrations. PRAS40 inhibits cell growth, S6K1 phosphorylation, and rhebinduced activation of the mTORC1 pathway, and in vitro it prevents the great increase in mTORC1 kinase activity induced by rheb1-GTP. Insulin stimulates Akt/PKB-mediated phosphorylation of PRAS40, which prevents its inhibition of mTORC1 in cells and in vitro. We propose that the relative strengths of the rheband PRAS40-mediated inputs to mTORC1 set overall pathway activity and that insulin activates mTORC1 through the coordinated regulation of both.
SUMMARY
The heterotrimeric mTORC1 protein kinase nucleates a signaling network that promotes cell growth in response to insulin and becomes constitutively active in cells missing the TSC1 or TSC2 tumor suppressors. Insulin stimulates the phosphorylation of S6K1, an mTORC1 substrate, but it is not known how mTORC1 kinase activity is regulated. We identify PRAS40 as a raptor-interacting protein that binds to mTORC1 in insulin-deprived cells and whose in vitro interaction with mTORC1 is disrupted by high salt concentrations. PRAS40 inhibits cell growth, S6K1 phosphorylation, and rhebinduced activation of the mTORC1 pathway, and in vitro it prevents the great increase in mTORC1 kinase activity induced by rheb1-GTP. Insulin stimulates Akt/PKB-mediated phosphorylation of PRAS40, which prevents its inhibition of mTORC1 in cells and in vitro. We propose that the relative strengths of the rheband PRAS40-mediated inputs to mTORC1 set overall pathway activity and that insulin activates mTORC1 through the coordinated regulation of both.
INTRODUCTION
The evolutionarily conserved TOR pathway is a critical controller of growth in eukaryotes, regulating cell as well as organ and body size in a variety of organisms (reviewed in Sarbassov et al. [2005] , Wullschleger et al. [2006] ). The pathway was discovered in studies into the mechanism of action of rapamycin, an immunosuppressive and antirestenosis drug that is also in clinical trials as a cancer therapy. The mammalian TOR (mTOR) pathway integrates signals from growth factors, nutrients, and stresses to regulate many growth-related processes, including mRNA translation, small molecule metabolism, cell survival, and autophagy. Emerging evidence indicates that deregulation of the mTOR pathway occurs in common diseases, including cancer and diabetes, underscoring the importance of identifying and understanding the function of the components of the mTOR signaling network.
The central component of the pathway, the large protein kinase mTOR, nucleates two distinct multiprotein complexes called mTOR complex 1 (mTORC1) and 2 (mTORC2) (reviewed in Sabatini [2006] ). mTORC1 is a heterotrimer consisting of the mTOR catalytic subunit and two associated proteins, raptor and mLST8/GbL. mTORC2 also contains mTOR and mLST8/GbL, though it contains the rictor and mSin1 proteins instead of raptor.The molecular functions of most mTOR-associated proteins are not understood, but raptor has been proposed to be a docking site for substrates on mTORC1 and to regulate mTOR kinase activity (Hara et al., 2002; Kim et al., 2002; Nojima et al., 2003; Schalm et al., 2003) . The best-characterized downstream effectors of mTORC1 are S6 Kinase 1 (S6K1) and 4E-BP1, two translational regulators that mTORC1 directly phosphorylates (Brunn et al., 1997; Burnett et al., 1998; Gingras et al., 2001) .
As judged by the phosphorylation state of S6K1 or 4E-BP1, the mTORC1 pathway senses many upstream signals, including growth factors like insulin as well as environmental nutrient levels. The mechanisms underlying mTORC1 regulation are not well understood, but a key upstream player is clearly the GTP binding protein rheb, which is negatively regulated by the dimeric TSC1-TSC2 GTPase-activating protein (GAP) (Castro et al., 2003; Garami et al., 2003; Inoki et al., 2003a; Saucedo et al., 2003; Stocker et al., 2003; Tee et al., 2002 Tee et al., , 2003b Zhang et al., 2003) . When TSC1 or TSC2 is lost, such as in the cancer-prone syndrome tuberous sclerosis complex (TSC), rheb becomes constitutively loaded with GTP, rendering the mTORC1 pathway active and insensitive to insulin. It is now appreciated that several pathways in addition to the insulin-stimulated PI3K/ Akt pathway signal to mTORC1 by modulating TSC1-TSC2 activity toward rheb. For example, energy deprivation sensed by AMPK (Inoki et al., 2003b) , MAPK signaling (Ma et al., 2005; Roux et al., 2004; Tee et al., 2003a) , and hypoxia and stress sensing (Brugarolas et al., 2004; Corradetti et al., 2005; Reiling and Hafen, 2004) all regulate TSC1-TSC2 activity and the GTP loading of rheb. Within cells, rheb overexpression strongly activates the mTORC1 pathway, and the overexpressed protein binds to the mTOR kinase domain (Long et al., 2005) . However, it is still not clear if endogenous rheb acts by binding directly to mTORC1 or if it requires an unknown intermediate.
Here, we identify PRAS40 as a raptor binding protein that potently inhibits mTORC1 kinase activity in vitro and mTORC1 signaling within cells. Insulin-stimulated phosphorylation of PRAS40 by Akt/PKB suppresses its mTORC1 inhibitory activity. Thus, we propose that insulin activates mTORC1 through the coordinated regulation of rheb, an mTORC1 activator, and PRAS40, an mTORC1 inhibitor.
RESULTS

A Salt-Sensitive Factor Inhibits the Kinase Activity of mTORC1
We previously developed protocols for immunopurifying intact mTORC1 and an in vitro assay for measuring its kinase activity toward full-length S6K1 (Guertin et al., 2006) . Surprisingly, this assay does not detect any difference between the activity of mTORC1 from serum-deprived and insulin-stimulated HEK293E cells, even though insulin robustly increases S6K1 phosphorylation in these cells ( Figure 1A ). We speculated that an unknown factor important for conferring insulin sensitivity is lost from mTORC1 during the washing of immunoprecipitates with buffers containing high salt concentrations. Indeed, when washed with buffers containing 150 but not 300 or 400 mM NaCl, mTORC1 from insulin-stimulated cells has much higher activity than that from serum-deprived cells ( Figure 1B) . By avoiding high salt buffers, we showed that insulin also activates endogenous mTORC1 from HeLa cells and mouse embryonic fibroblasts (MEFs) ( Figure 1C ), as well as mTORC1 containing recombinant HA-raptor stably expressed in HEK293E cells ( Figure 1D ). High salt washing eliminates the insulin-induced difference in mTORC1 activity by increasing the activity of mTORC1 from serumdeprived cells ( Figure 1B ). This indicates that a saltsensitive factor inhibits mTORC1 during insulin deprivation and suggests that loss or repression of this factor participates in activating mTORC1 in response to insulin.
Inactivation of the TSC1 or TSC2 tumor suppressor leads to insulin-insensitive and constitutively high S6K1 phosphorylation (Garami et al., 2003; Inoki et al., 2002; Manning et al., 2002; Zhang et al., 2003) . Paradoxically, however, we find that the in vitro kinase activity of mTORC1 from TSC2 null MEFs treated with or without insulin is very repressed, being similar in magnitude to that of mTORC1 from wild-type MEFs deprived of insulin ( Figure 1E ). Substantial evidence (Harrington et al., 2004; Shah et al., 2004) indicates that hyperactive mTORC1 signaling downregulates the insulin/PI3K pathway so that TSC2 null MEFs are in a state equivalent to insulin deprivation. Consistent with this, high salt washes activate mTORC1 from TSC2 null MEFs ( Figure 1E ), just as they do mTORC1 from insulin-deprived wild-type MEFs ( Figure 1E ) or HEK293E cells ( Figure 1B) . Thus, in TSC2 null MEFs, an mTORC1 activator must exist that overcomes repression of mTORC1 by the salt-sensitive inhibitor and leads to the hyperactive mTORC1 signaling characteristic of these cells. Such an activator is likely lost from mTORC1 during its purification, explaining the low in vitro activity of mTORC1 from TSC2 null cells.
An obvious candidate for such an mTORC1 activator is rheb-the small GTPase that becomes constitutively loaded with GTP in the absence of TSC1 or TSC2. Previous studies show that overexpressed rheb1 strongly activates the mTORC1 pathway and binds to the mTOR kinase domain (Long et al., 2005) . We confirmed these studies (data not shown), but, despite considerable effort, we were unable to detect endogenous rheb bound to immunopurified mTORC1 (data not shown), probably because the rheb-mTORC1 interaction is transient and too weak to survive even the gentlest immunopurifications. Thus, to determine if rheb can activate mTORC1 in vitro, we added GTP-loaded rheb1 or control proteins to mTORC1 immunopurified under low salt conditions and measured its kinase activity toward S6K1. Rheb1-GTP, but not rheb1-GDP, rap2a-GTP, or rap2a-GDP, dramatically activated endogenous (Figure 2A ) or recombinant ( Figure 2C ) mTORC1 from serum-deprived HEK293E cells and also boosted the activity of mTORC1 from insulinstimulated cells ( Figure 2B ). Rheb1-GTP also strongly activated mTORC1 from TSC2 null MEFs ( Figure 2D ). Lastly, rheb1-GTP also activated mTORC1 kinase activity toward 4E-BP1 ( Figure 2E ). To our knowledge, these are the first demonstrations that soluble GTP-loaded rheb1 directly activates mTORC1 in vitro. We conclude that rheb1-GTP can overcome, like high salt washes, the suppression of in vitro mTORC1 activity caused by insulin deprivation or TSC2 null status, suggesting that rheb1-GTP can counter the actions of the salt-sensitive inhibitor.
PRAS40 Is a Raptor Binding Protein that Interacts with mTORC1
To identify the salt-sensitive inhibitor of mTORC1, we searched for proteins that copurify with mTORC1 when raptor or mTOR immunoprecipitates are washed with buffers containing low but not high salt concentrations. This led to the identification by mass spectrometry of PRAS40, a 28 kDa proline-rich protein lacking named domains but which is known to be phosphorylated near its C terminus by Akt/PKB (Kovacina et al., 2003) and potentially other kinases (Huang and Porter, 2005) (Figure 3A) . Interestingly, the gene for PRAS40 (called AKT1S1) is located at chromosome 19q13.33, a region thought to contain an unknown tumor suppressor associated with gliomas (Hartmann et al., 2002) . PRAS40 is not conserved in budding or fission yeast but has a putative Drosophila ortholog named Lobe (Chern and Choi, 2002) .
By using immunoblot analyses of raptor immunoprecipitates, we confirmed that PRAS40 copurifies with endogenous mTORC1, but not a control protein, when it is isolated under low salt conditions and that high salt washes greatly reduce the amount of PRAS40 bound to mTORC1 ( Figure 3B ). In HEK293E cells, acute insulin stimulation of serum-deprived cells decreases the amount of PRAS40 bound to mTORC1 without affecting its expression level ( Figure 3B ). mTOR is part of two distinct complexes within cells, mTORC1 and mTORC2, but PRAS40 only interacts with mTORC1 ( Figure 3C ). Endogenous PRAS40 interacts, in an insulin-sensitive fashion, with mTORC1 containing recombinant raptor ( Figure 3D ), suggesting that recombinant proteins can be used to identify the PRAS40 binding site on mTORC1. To do so, we coexpressed Flag-PRAS40 with HA-raptor and/or myc-mTOR and isolated mTORC1 using anti-HA or anti-myc immunoprecipitations ( Figure 3E ). PRAS40 robustly coimmunoprecipititates with HA-raptor and the coexpression of myc-mTOR did not significantly increase the amount of PRAS40 recovered with HA-raptor. While relatively small amounts of PRAS40 coimmunoprecipitate with myc-mTOR, the coexpression of HA-raptor significantly increases the amount of PRAS40 recovered with myc-mTOR. These results indicate that PRAS40 preferentially binds the raptor component of mTORC1 and are consistent with PRAS40 not binding to mTORC2, which does not contain raptor. PRAS40 binds better to the N-than to (A) When mTORC1 is washed with buffers containing high salt concentrations, there is no difference in the kinase activity of mTORC1 isolated from serumdeprived or insulin-treated cells. HEK293E cells were deprived of serum for 14 hr or serum-deprived and treated with 150 nM insulin for 15 min. mTOR immunoprecipitates were prepared from cell lysates (1 mg total protein), washed with buffers containing 500 mM NaCl, and analyzed for mTORC1 kinase activity toward S6K1 and levels of mTOR and raptor. Lysates were analyzed by immunoblotting for indicated proteins and phosphorylation states. (B) An insulin-stimulated difference in mTORC1 activity is detected only when mTORC1 is washed with low salt buffers. mTOR immunoprecipitates from HEK293E cells treated as in (A) were washed with buffers containing 400, 300, or 150 mM NaCl and analyzed for mTORC1 kinase activity. (C) Raptor immunoprecipitates were prepared from indicated cell types that had been serum deprived and treated with insulin as in (A), washed with buffers containing 150 mM NaCl, and analyzed for mTORC1 activity. Cell lysates were analyzed by immunoblotting for levels of indicated proteins. (D) HA immunoprecipitates from HEK293E cells stably expressing HA-raptor were prepared and analyzed for mTORC1 activity as in (C).
(E) Raptor immunoprecipitates from TSC2
À/À or TSC2 +/+ MEFs treated as in (A) were washed with buffers containing 150 mM or 500 mM NaCl and analyzed for mTORC1 activity. Cell lysates were analyzed by immunoblotting for levels of indicated proteins and phosphorylation states.
the C-terminal half of raptor, but the degree of binding obtained to all raptor fragments tested is much less than that to full-length raptor (data not shown). Consistent with PRAS40 binding to raptor, in cells with RNAi-induced partial decreases in raptor or mTOR expression, the amount of PRAS40 recovered in raptor or mTOR immunoprecipitates correlates with the amount of raptor, but not mTOR, in the immunoprecipitates ( Figure 3F ). Because previous work (Kovacina et al., 2003) indicates that PRAS40 is phosphorylated on T246 in an Akt/PKBdependent fashion, we asked how insulin affects the phosphorylation status of PRAS40 bound to mTORC1 ( Figure 3G ). As expected, lysates of HEK293E and HeLa cells treated with insulin had much greater levels of phosphorylated PRAS40 than lysates of serum-deprived cells. Despite the fact that insulin decreases the amount of PRAS40 bound to mTORC1 in HEK293E and HeLa cells, the PRAS40 that remains bound is highly phosphorylated. Thus, PRAS40 phosphorylation does not preclude the binding of PRAS40 to mTORC1, although it may weaken the interaction. This is consistent with the results of similar experiments in wild-type MEFs, where insulin causes a large increase in the phosphorylation of the PRAS40 that is bound to mTORC1 but only a modest decrease in the amount of total PRAS40 bound to mTORC1 ( Figure 3G ). In TSC2 null MEFs, insulin does not increase PRAS40 phosphorylation, as expected from the profound inhibition of insulin signaling and Akt/PKB activity in these cells ( Figure 3G ). The fact that PRAS40 phosphorylation on T246 positively correlates with the in vitro activation of mTORC1 by insulin suggests that this phosphorylation event may promote mTORC1 activation.
Phosphorylation of PRAS40 at T246 is unlikely to be a major component of the mechanism through which amino acids signal to mTORC1. Leucine stimulation of wild-type and TSC2 null MEFs and HEK293E cells only had small effects on the phosphorylation of PRAS40 at T246 and the amount of PRAS40 bound to mTORC1 (see Figure S1 in the Supplemental Data available with this article online).
PRAS40 Is an Inhibitor of mTORC1 In Vitro
To begin to investigate potential roles for PRAS40 in the regulation of the mTORC1 pathway, we asked if it affects mTORC1 kinase activity in vitro. We have described three ways of obtaining active mTORC1: (1) by washing mTORC1 from serum-deprived cells with buffers containing high salt concentrations, (2) by immunopurifying mTORC1 from cells stimulated with insulin, or (3) by adding rheb1-GTP to mTORC1 from serum-deprived cells. In the (E) The experiment was performed as in (B) using 4E-BP1 as a substrate.
experiments described below, we tested the in vitro effect of PRAS40 on mTORC1 activity using recombinant PRAS40 overexpressed in and purified from HEK293T cells. In a dose-sensitive fashion, PRAS40, but not a control protein, inhibited the in vitro kinase activity of mTORC1 activated with high salt washes ( Figure 4A ) or insulin stimulation ( Figures 4B and 4F ). PRAS40 is a potent inhibitor, with half-maximal inhibition occurring at or below 20 nM. PRAS40 also blocks the massive activation of mTORC1 caused by 100 nM GTP-loaded rheb1 ( Figure 4C ), and, as is the case with activation caused by high salt washes or insulin stimulation, half-maximal inhibition occurred at In HEK293E cells, the interaction of PRAS40 with mTORC1 is regulated by insulin and disrupted in vitro by high salt-containing buffers. Raptor or p53 immunoprecipitates were prepared from HEK293E cells deprived of serum for 14 hr or serum deprived and treated with 150 nM insulin for 15 min.
Immunoprecipitates were washed with buffers containing 400 or 150 mM NaCl and analyzed by immunoblotting for indicated proteins. In cell lysates, levels of PRAS40 do not change upon insulin stimulation. (C) PRAS40 binds to mTORC1 and not mTORC2. Raptor and rictor immunoprecipitates were prepared from HEK293E cells treated with insulin as in (B), washed with buffers containing 150 mM NaCl, and analyzed by immunoblotting for the indicated proteins.
(D) Endogenous PRAS40 binds to mTORC1-containing recombinant epitope-tagged raptor. Flag immunoprecipitates from HEK293E cells expressing Flag-raptor or a control vector and treated as in (C) were prepared and washed with buffers containing 150 mM NaCl and analyzed by immunoblotting for the indicated proteins.
(E) PRAS40 preferentially binds the raptor component of mTORC1. Indicated cDNAs in expression vectors were cotransfected in HEK293E cells and cell lysates prepared. Half of each cell lysate was used to prepare HA immunoprecipitates and the other half for myc immunoprecipitates. Both were analyzed by immunoblotting for the indicated proteins. Cell lysates contain equal levels of Flag-PRAS40. Samples in which cDNAs for raptor and mTOR were cotransfected were performed in duplicate.
(F) PRAS40 association with mTORC1 requires raptor. HEK293E cells were infected with the specified lentiviral shRNAs and mTOR and raptor immunoprecipitates were analyzed by immunoblotting for the levels of the indicated proteins.
(G) In HEK293E and HeLa cells and wild-type but not TSC2 null MEFs, insulin stimulates the phosphorylation of the PRAS40 bound to mTORC1. Cells were treated with and without insulin as in (B). Raptor immunoprecipitates and cell lysates were analyzed for the levels of the indicated proteins and phosphorylation states.
around 20 nM PRAS40 ( Figure 4D ). Thus, PRAS40 is a potent inhibitor of mTORC1 and accounts for the saltsensitive inhibition of mTORC1 we observe. It is clear that PRAS40 can inhibit rheb1-GTP activation of mTORC1, but several of the findings we have presented also strongly suggest that at high concentrations rheb1-GTP can overcome PRAS40-mediated inhibition of mTORC1. For example, the addition of rheb1-GTP to mTORC1 from serum-deprived 293E (Figures 2A-2C ) or TSC2 null ( Figure 2D ) cells-two situations where PRAS40 is bound to mTORC1-stimulates mTORC1 activity. To formally prove that rheb1-GTP can reverse PRAS40-mediated inhibition of mTORC1, we incubated mTORC1 with a constant amount of PRAS40 (40 nM) and increasing amounts of rheb1-GTP and measured mTORC1 kinase activity. Indeed, in a dose-sensitive fashion, rheb1-GTP reactivates PRAS40-inhibited mTORC1 ( Figure 4E ). PRAS40 (40 nM) completely inhibits mTORC1 obtained from insulin-stimulated cells, and a 9-fold higher concentration (360 nM) of rheb1-GTP is required to restore mTORC1 activity. These results indicate that at elevated levels of rheb1-GTP-as would be expected in TSC2 null cellsthe molar ratio of rheb1-GTP to PRAS40 is sufficiently high to overcome inhibition of mTORC1 by PRAS40.
PRAS40 Is an Inhibitor of the mTORC1 Pathway in Mammalian Cells
To determine if the in vivo correlates of our in vitro findings are true, we began by using overexpression to test the effects of PRAS40 on the mTORC1 pathway within cells. In HEK293E cells, transient overexpression of PRAS40, but not a control protein, blocks the insulin-induced phosphorylation of T389 on coexpressed S6K1 ( Figure 5A ). Furthermore, coexpression of PRAS40 with rheb1 eliminates the very large increase in S6K1 phosphorylation that is normally caused by the overexpression of rheb1 in HEK293E and HEK293T cells ( Figure 5B ). When stably overexpressed using retroviral transduction, PRAS40 reduces cell size in HEK293E cells ( Figure 5C ). Moreover, stable overexpression of PRAS40 in TSC2 null MEFs reduces the enlarged cell phenotype of these cells (A) PRAS40 inhibits mTORC1 activated by washing in high salt-containing buffers. HA-raptor immunoprecipitates were prepared from HEK293E cells stably expressing HA-raptor deprived of serum for 14 hr or serum-deprived and treated with 150 nM insulin for 20 min. Immunoprecipitates were washed with buffers containing 150 or, where indicated, 500 mM NaCl. mTORC1 kinase assays containing the specified concentrations of PRAS40 or tubulin were performed and analyzed by immunoblotting for the indicated proteins and phosphorylation states. (B) PRAS40 inhibits active mTORC1 isolated from insulin-stimulated HEK293E cells. The experiment was performed and analyzed as in (A) except that all immunoprecipitates were washed with buffers containing 150 mM NaCl. (C) PRAS40 blocks mTORC1 activation induced by GTP-loaded rheb1. The experiment was performed and analyzed as in (A) except that all immunoprecipitates were from serum-deprived cells and washed with buffers containing 150 mM NaCl. Kinase assays contained 100 nM rheb1 or rap2a loaded with GDP or GTP. (D) PRAS40 blocks, in a dose-sensitive fashion, mTORC1 activation induced by GTP-loaded rheb1. The experiment was performed and analyzed as in (C) using indicated concentrations of rheb1-GTP and PRAS40. (E) At high ratios of rheb1-GTP to PRAS40, rheb1-GTP can overcome PRAS40-mediated suppression of mTORC1. Experiment was performed and analyzed as in (D). (F) PRAS40 inhibits mTORC1 activity toward 4E-BP1. Experiment was performed as in (B) using mTORC1 obtained from insulin-stimulated cells and 4E-BP1 as the substrate.
( Figure 5C ). Thus, as in vitro, PRAS40 overexpression within cells strongly inhibits the mTORC1 pathway.
Because PRAS40 overexpression is sufficient to inhibit the mTORC1 pathway, we asked if endogenous PRAS40 normally has an inhibitory function within cells. Our expectation was that if PRAS40 plays a role in the mTORC1 pathway inhibition that occurs in insulin-deprived cells, a loss of PRAS40 expression should boost the phosphorylation state of S6K1 even in the absence of insulin. Indeed, using two independent PRAS40-directed lentivirally expressed shRNAs, knockdowns of PRAS40 in wild-type MEFs and in human HT-29 colon cancer cells increased the phosphorylation of S6K1 in serum-deprived cells ( Figures 5D and 5E ). The increase in S6K1 phosphorylation caused by the PRAS40 knockdown was not as great as that caused by insulin stimulation, but this is not surprising, because in the absence of insulin, cells are missing the mTORC1-activating input coming from rheb. In addition, the mTORC1 and S6K1 activation caused by the PRAS40 knockdown should trigger feedback inhibition of PI3K/Akt signaling, which will suppress rheb and thus limit mTORC1 activation. A knockdown of PRAS40 Figure 5 . In Mammalian Cells, PRAS40 Inhibits mTORC1 Signaling and Cell Growth (A) Overexpression of PRAS40 inhibits insulin-mediated phosphorylation of S6K1. HEK293E cells were cotransfected with expression plasmids for HA-GST-S6K1 (500 ng) as well as myc-tubulin or myc-PRAS40 (2 mg), serum deprived for 14 hr or serum deprived and treated with 150 nM insulin for 15 min. Cell lysates were analyzed by immunoblotting for the levels of the indicated proteins and phosphorylation states. (B) Overexpression of PRAS40 inhibits the large increase in S6K1 phosphorylation caused by the overexpression of rheb1. HEK293E cells were cotransfected with expression plasmids for HA-GST-S6K1 (500 ng) and 2 mg of the other specified plasmids. In HEK293T cells, 50 ng was used of the HA-GST-S6K1 expression plasmid and 1 mg of the other plasmids. Cell lysates were prepared and analyzed by immunoblotting for the levels of the indicated proteins and phosphorylation states. (C) Stable overexpression of PRAS40 inhibits cell size. HEK293E cells or TSC2 null MEFs were infected with retroviruses expressing PRAS40 or tubulin, and 48 hr later cell size was measured using a Coulter counter. (D) Validation of shRNAs directed against human or mouse PRAS40. HT-29 cells or wild-type MEFs were infected with lentiviruses expressing shRNAs targeting mouse or human PRAS40, respectively, and cell lysates analyzed by western blotting for the indicated proteins. Control shRNAs targeted raptor or luciferase. (E) Knockdown of endogenous PRAS40 activates the mTORC1 pathway. Wild-type MEFs or HT-29 cells infected with lentiviruses expressing shRNAs targeting the indicated genes were incubated in the presence or absence of serum for 3 hr. Cell lysates were analyzed by immunoblotting for the levels of the indicated proteins and phosphorylation states. expression only slightly increased the phosphorylation of S6K1 in cells growing in the presence of insulin ( Figure 5E ), suggesting that insulin represses the inhibitory properties of PRAS40.
Lobe Is an Inhibitor of the dTORC1 Pathway in Drosophila Cells
The inhibitory function of PRAS40 on the mTORC1 pathway is conserved in Drosophila tissue culture cells. Transfection into S2 cells of two distinct nonoverlapping RNAiinducing dsRNAs against Lobe, the PRAS40 ortholog, increased dS6K phosphorylation and cell diameter, although not to as large of an extent as a dsRNA-targeting dTSC2 ( Figures 6A and 6B) . In Kc167 cells, the sequential knockdown of dTOR and then Lobe blocks the increase in dS6K phosphorylation caused by the solo knockdown of Lobe, consistent with Lobe being upstream of dTOR ( Figure 6C ). In contrast, Lobe function does not depend on dRheb, as the sequential knockdown of dRheb and then Lobe partially restores the levels of dS6K phosphorylation compared to cells having a knockdown of dRheb alone. Using cell size as a phenotype, we next used the Figure 6 . In Drosophila Cells, Lobe Inhibits dTORC1 Signaling and Cell Growth (A) A knockdown of Lobe using two distinct dsRNAs increases dS6K phosphorylation. S2 cells were transfected with the indicated dsRNAs as described in the Experimental Procedures. (B) A knockdown of Lobe increases the mean size of S2 cells. Cells were transfected as in (A) with the GFP, Lobe #1, Lobe #2, or dTSC2 dsRNAs and cell size measured with a Coulter counter. Mean cells diameters ± standard error for n = 3 are as follows: GFP dsRNA, 10.71 ± 0.02 mm; Lobe #1 dsRNA, 10.98 ± 0.03 mm; Lobe #2 dsRNA, 10.95 ± 0.04 mm; dTSC2 dsRNA, 11.26 ± 0.02 mm. The differences in cell diameter between cells transfected with the GFP dsRNA and the Lobe or dTSC2 dsRNAs is significant to at least p < 0.05. For clarity, histogram shows data for only one of the Lobe dsRNAs. (C) A Lobe knockdown suppresses the decrease in dS6K phosphorylation caused by a knockdown of dRheb but not of dTOR. Kc167 cells were transfected as described in the Experimental Procedures. Cell lysates were analyzed with immunoblotting for the levels and phosphorylation states of the indicated proteins. (D) A knockdown of Lobe increases S2 cell size in a dTOR-dependent but dRheb-independent fashion. Cells were transfected as in (C) with the indicated dsRNAs, and cell sizes were measured 24 hr after the final transfection. Cell volumes were normalized within each group of three in order to compare the cell volume changes that occur when Lobe or dTSC2 is knocked down alone or together with dRheb or dTOR. Error bars indicate standard error for n = 3. most active Lobe dsRNA to place Lobe within the dTOR pathway Lobe with respect to dRheb and dTOR (Figure 6D) . The sequential knockdown of dRheb and then Lobe did not alter the approximately 10% increase in mean cell volume caused by the knockdown of Lobe alone, which is consistent with Lobe function not depending on dRheb. On the other hand, the sequential knockdown of dRheb and then dTSC2 completely blocked the increase in cell size caused by the knockdown of dTSC2 alone, in accord with the established placement of dRheb downstream of dTSC2 (Gao et al., 2002; Saucedo et al., 2003; Stocker et al., 2003; Zhang et al., 2003) . The sequential knockdown of dTOR and then either Lobe or dTSC2 eliminated the increase in cell size caused by the knockdown of Lobe or dTSC2 alone ( Figure 6D ). This is consistent with dTOR being downstream of both Lobe and dTSC2 and required for the cell size increases caused by the Lobe and dTSC2 knockdowns. We conclude that, in mammalian and Drosophila cells, PRAS40 negatively regulates the TORC1 pathway.
Akt/PKB-Mediated Phosphorylation of PRAS40 Blocks Its Inhibitory Activity toward mTORC1
Insulin-stimulated activation of the in vitro kinase activity of mTORC1 correlates with an increase in the T246 phosphorylation of the PRAS40 bound to mTORC1, suggesting that this phosphorylation event may relieve the inhibitory action of PRAS40 on mTORC1 ( Figures 1A-1E and 3G ). As Akt/PKB is an insulin-stimulated kinase that phosphorylates PRAS40 on T246 (Kovacina et al., 2003) , we hypothesized that Akt/PKB activates mTORC1 by phosphorylating and suppressing PRAS40. The in vitro addition of active T308D Akt/PKB and ATP to mTORC1 obtained from serum-deprived cells substantially increases mTORC1 kinase activity ( Figure 7A ). Consistent with a key role for PRAS40 in this activation, Akt/PKB does not activate mTORC1 that has been washed with buffers containing high salt concentrations, conditions that strip off PRAS40 ( Figure 3B ). To directly test the role of PRAS40 phosphorylation on mTORC1 activity, we generated phosphorylated PRAS40 by incubating it with active Akt/PKB and ATP. As a control, we mock phosphorylated PRAS40 by incubating it with active Akt/PKB in the absence of ATP. As before (Figure 4A ), the addition of 40 nM nonphosphorylated PRAS40 strongly inhibited the activity of mTORC1 washed with buffers containing high salt concentrations, while, in contrast, the equivalent amount of phosphorylated PRAS40 had a much-reduced inhibitory effect ( Figure 7B ). These results suggest that, although 14-3-3 proteins interact with phosphorylated PRAS40 (Kovacina et al., 2003) , the binding of 14-3-3 to PRAS40 is not necessary to repress the inhibitory function of PRAS40 on the in vitro kinase activity of mTORC1. Of course, it is possible that 14-3-3 does have a necessary role within cells that we do not detect in vitro.
To confirm the role of PRAS40 phosphorylation in regulating mTORC1 within cells, we coexpressed in HEK293E cells an HA-GST-S6K1 reporter together with low amounts of wild-type or T246A mutant PRAS40 and stimulated the cells with insulin ( Figure 7C ). As expected, insulin strongly boosted the T389 phosphorylation of the S6K1 reporter, and the low amounts of coexpressed wild-type PRAS40 only weakly diminished this phosphorylation. On the other hand, the expression of the T246A mutant of PRAS40 completely blocked insulin-stimulated phosphorylation of T389 of S6K1 ( Figure 7C ). We obtained equivalent results in a conceptually similar experiment in which we used the expression of constitutively active Akt/PKB (myr-Akt) instead of insulin to promote S6K1 phosphorylation ( Figure 7D ). As with insulin, the expression of low amounts of T246A, but not wild-type, PRAS40 mutant blocked the increase in T389 phosphorylation caused by the expression of constitutively active Akt/PKB. Thus, both in vitro and within cells, Akt/PKBmediated phosphorylation of PRAS40 represses its inhibitory function.
DISCUSSION
A frustrating aspect of studying mTORC1 has been the difficulty of preserving its regulation in vitro. Even when isolated from cells with vastly different levels of mTORC1 signaling (like serum-deprived and insulin-stimulated cells), the mTORC1 obtained through most purification protocols exhibits at best modest differences in mTORC1 kinase activity. Using a newly developed purification protocol and mTORC1 kinase assay, we provide two findings that help explain this discrepancy. First, the in vitro addition of soluble rheb1-GTP to mTORC1 dramatically activates mTORC1 kinase activity, but even the gentlest purification schemes do not preserve the interaction between endogenous mTORC1 and rheb. Therefore, in cellular states in which rheb plays a major role in activating the mTORC1 pathway-like in insulin-stimulated cells-the in vitro kinase activity of mTORC1 will be artificially low and not reflect true mTORC1 activity within cells. Second, we identify PRAS40 as a raptor binding protein that inhibits mTORC1 activity in vitro and mTORC1 signaling within cells. PRAS40 is largely lost from mTORC1 under purification conditions in which its core, evolutionarily conserved components-mTOR, raptor, and mLST8/ GbL-remain together. Thus, as PRAS40 negatively regulates the mTORC1 kinase, its loss artifactually increases the in vitro activity of mTORC1 from insulin-deprived cells.
The fact that both PRAS40 and rheb-GTP strongly regulate mTORC1 activity raises the question of which protein is the predominant regulator of mTORC1 in cells. Our overexpression and in vitro work shows that either regulator is capable of overcoming the effects of the other. However, in normal cells, insulin-stimulated Akt/PKB signaling aligns the activities of PRAS40 and rheb so that both push mTORC1 activity in the same direction ( Figure 7E ). That is, in insulin-treated cells, phosphorylated PRAS40 does not repress mTORC1, while GTP-loaded rheb activates it. In serum-deprived cells, dephosphorylated PRAS40 represses mTORC1, while GDP-loaded rheb does not activate it. So far, we know of only one signaling state, that of TSC2 null MEFs, in which PRAS40 and rheb push mTORC1 activity in opposite directions ( Figure 7E ). In these cells, rheb is constitutively loaded with GTP, while PRAS40 is in its dephosphorylated inhibitory state because of suppressed insulin signaling. The high and constitutive activity of mTORC1 within TSC2 null MEFs indicates that hyperactive rheb can overcome PRAS40-mediated inhibition of mTORC1. Interestingly, the battle between PRAS40 and rheb1-GTP can be observed in vitro. The kinase activity of mTORC1 purified from TSC2 null MEFs under conditions that preserve the PRAS40 interaction is very low but can be activated by the in vitro addition of rheb1-GTP or removal of PRAS40.
The relative strengths of the rheb and PRAS40 inputs to the mTORC1 pathway may vary in different cell types depending on the activity and abundance of each protein.
In the serum-deprived cells we have examined, partial depletion of PRAS40 has modest activating effects on the mTORC1 pathway, presumably because in the absence of insulin the positive signal from rheb to mTORC1 is missing. Although our work has focused on the coordinated regulation of rheb and PRAS40 by insulin, it is likely that pathways exist that can signal to PRAS40 and rheb independently, allowing cells to fine-tune mTORC1 activity to specific environmental conditions.
A recent parallel study also identifies PRAS40 as an mTORC1-interacting protein (Haar et al., 2007) and (A) The addition of active T308D Akt/PKB stimulates the kinase activity of mTORC1 washed with low but not high salt buffers. Raptor immunoprecipitates from serum-deprived cells were washed with buffers containing 150 or 500 mM NaCl as described in the Experimental Procedures. mTORC1 kinase activity in the immunoprecipitates was assayed in the presence or absence of 400 ng active Akt/PKB and levels, and phosphorylation state of S6K1 was analyzed by immunoblotting. (B) PRAS40 phosphorylated by Akt/PKB has a reduced capacity to inhibit mTORC1. Nonphosphorylated or phosphorylated PRAS40 (40 nM) was added to mTORC1 immunoprecipitates washed with high salt. Kinase assays were performed and analyzed by immunoblotting for the levels of the indicated proteins and phosphorylation states. (C) Expression of T246A PRAS40 blocks insulin-stimulated phosphorylation of S6K1. HEK293E were cotransfected with expression plasmids for HA-GST-S6K1 (500 ng) as well as low (25 ng) or high (250 ng) amounts of expression plasmids for wild-type or T246A myc-PRAS40. Of the plasmid encoding myc-tubulin, 250 ng was used. Cells were deprived of serum or serum deprived and stimulated with 150 nM insulin for 20 min. Cell lysates were analyzed by immunoblotting for the levels of the indicated proteins and phosphorylation states. (D) Expression of T246A PRAS40 blocks phosphorylation of S6K1 induced by the expression of constitutively active myristoylated Akt/PKB (myr-Akt). HEK293E cells were cotransfected and analyzed as above except that 2 mg of the expression plasmid for myr-Akt was included. The increasing amounts of PRAS40 expression vectors used were 3, 10, 30, 100, and 300 ng. (E) Models depicting regulation of mTORC1 signaling by rheb and PRAS40 in insulin-treated (+Insulin), serum-deprived (ÀInsulin), and TSC2 null (TSC2 À/À ) cells. Green and red colors indicate active and inactive components and signaling events, respectively. In insulin-treated cells, GTP-loaded rheb stimulates mTORC1, while phosphorylated PRAS40 does not repress mTORC1. In serum-deprived cells, GDP-loaded rheb is inactive, while dephosphorylated PRAS40 represses mTORC1. In TSC2 null cells, GTP-loaded rheb overcomes the mTORC1 inhibition mediated by dephosphorylated PRAS40.
focuses on its role in modulating the feedback loop between mTORC1 and the IRS/PI3K pathway. While this study shows that PRAS40 suppresses mTORC1 signaling within cells, our in vitro data reveal that PRAS40 is a direct inhibitor of the mTORC1 kinase and that it antagonizes the activation of mTORC1 caused by rheb1-GTP. We also come to differing conclusions on a number of important points. First, a key question is whether PRAS40 or rheb1 plays the dominant role in establishing mTORC1 activity within cells. Haar et al. (2007) conclude from experiments based on tissue culture cells that PRAS40 has dominant effects over the TSC1/TSC2-rheb axis. However, our results with TSC2 null MEFs and in vitro kinase assays suggest that the situation is more complicated and that either component can overcome the effects of the other when sufficiently activated. Second, our in vitro data suggest that 14-3-3 binding is not required for the Akt/PKB-mediated repression of PRAS40, though we acknowledge that 14-3-3 may play a role in insulin stimulation of mTORC1 within cells. Third, Haar et al. (2007) describe PRAS40 as an mTOR binding protein, but we find clear evidence for preferential binding to raptor, a result that is more consistent with the finding that PRAS40 binds only to mTORC1. Fourth, we have been unable to observe any effect of amino acid signaling on the mTORC1-PRAS40 interaction and suspect that different cell lysis conditions between our two studies account for this discrepancy. In contrast to our previous work (Kim et al., 2002) , we have now developed mild lysis and purification conditions under which the integrity of the mTOR-raptor interaction is not affected by changes in environmental leucine levels. Haar et al. (2007) do not examine the effects of leucine on PRAS40 phosphorylation, and we believe that the leucine-induced decrease in the amount of PRAS40 recovered in mTOR immunoprecipitates correlates with a similar decrease in the amount of raptor bound to mTOR.
Given the complexity of the mTORC1 pathway and the presence of feedback loops between components, it is likely that a full understanding of the physiologic consequences of altering the rheb-PRAS40 balance will require the development of animal models overexpressing or missing these proteins.
EXPERIMENTAL PROCEDURES
Materials
Reagents were obtained from the following sources: antibodies to raptor, human PRAS40, and multispecies phospho-T246 PRAS40, as well as GTPgS, GDP, and T308D Akt/PKB from Upstate/Millipore; an antibody to mouse PRAS40 from Biosource; antibodies to mTOR, b-catenin, and S6K1 as well as HRP-labeled anti-mouse, anti-goat, and anti-rabbit secondary antibodies from Santa Cruz Biotechnology; antibodies to phospho-T389 S6K1, phospho-T37/T46 4E-BP1, phospho-S473 Akt/PKB, phospho-T398-dS6K, phospho-S505 dAkt, Akt (pan), 4E-BP1, and the myc epitope from Cell Signaling Technology; an antibody to HA from Bethyl Laboratories; Flag M2 affinity gel, Flag M2 antibody, ATP, and human recombinant insulin from Sigma Aldrich; protein G Sepharose and immobilized glutathione from Pierce; DMEM from SAFC Biosciences; LY294002 from Calbiochem; PreSci- The soluble fractions of cell lysates were isolated by centrifugation at 13,000 rpm for 10 min in a microcentrifuge. For immunoprecipitations, primary antibodies were added to the lysates and incubated with rotation for 1.5 hr at 4 C. A 50% slurry of protein G Sepharose (60 ml) was then added, and the incubation continued for an additional 1 hr. Immunoprecipitates were washed three times each with low salt wash buffer (40 mM HEPES [pH 7.4], 150 mM NaCl, 2 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, 0.3% CHAPS). When specified, wash buffers contained the indicated increased concentrations of NaCl. Immunoprecipitated proteins were denatured by the addition of 20 ml of sample buffer and boiling for 5 min, resolved by 8%-16% SDS-PAGE, and analyzed by immunoblotting as described (Kim et al., 2002) .
In Vitro Kinase Assay for mTORC1 Activity For kinases assays, immunoprecipitates were washed three times in low salt wash buffer, or once in low salt wash buffer followed by two additional washes in buffers containing the NaCl concentrations indicated in the figures. Immunoprecipates were then washed twice in 25 mM HEPES (pH 7.4), 20 mM potassium chloride. Kinase assays were performed for 20 min at 30 C in a final volume of 15 ml consisting of mTORC1 kinase buffer (25 mM HEPES [pH 7.4], 50 mM KCl, 10 mM MgCl 2 , 250 mM ATP) and 150 ng inactive S6K1 or 4E-BP1 as the substrate. Reactions were stopped by the addition of 30 ml of sample buffer and boiling for 5 min and analyzed by SDS-PAGE and immunoblotting. Note that the kinase assay buffer used in this work does not contain manganese, which is present in buffers we have used previously (Kim et al., 2002) . PRAS40, tubulin, rheb1, or rap2a was added to mTORC1 for 5-20 min before the addition of ATP to the kinase assay.
Preparation of S6K1, PRAS40, Phosphorylated PRAS40, rheb1, rap2a, and a-Tubulin for Use in mTORC1 Kinase Assays Full-length rat p70 S6K1 was cloned into an HA-GST pRK5 vector modified so as to contain a PreScission protease site between the GST tag and the initiator codon of S6K1. The expression construct was transfected into HEK293T cells using FuGENE 6, and, after 48 hr, the cells were treated with 20 mM LY294002 for 1 hr prior to cell harvesting and lysis. HA-GST-PreSciss-S6K1 was purified as described (Burnett et al., 1998) and the affinity tag removed with the PreScission protease. S6K1 was separated from free GST by gel filtration on a HiLoad 16/60 Superdex 200 column (Amersham) and the purified protein stored at À80 C in 20% glycerol.
Rheb1 or rap2a cDNAs in HA-GST-pRK5 were transfected as above into HEK293T cells. Cells were lysed with rheb lysis buffer (the lysis buffer used above but without EDTA and containing 5 mM MgCl 2 ), and cleared lysates were incubated with immobilized glutathione for 2 hr at 4 C. Beads were washed twice with rheb lysis buffer and once with rheb storage buffer (20 mM HEPES [pH 8.0], 200 mM NaCl, and 5 mM MgCl 2 ). GST-rheb1 and rap2a were eluted from the beads with 10 mM glutathione in rheb storage buffer. Eluted proteins were incubated with 10 mM EDTA and 1 mM GDP or 0.1 mM GTPgS at 30 C for 10 min. MgCl 2 (20 mM) was then added and the proteins kept on ice until use. PRAS40 or a-tubulin cDNAs in Flag-pRK5 were transfected into HEK293T cells, the cells treated with 20 mM LY294002 for 15 min prior to lysis, and the proteins purified using immobilized Flag-antibody resin. Proteins were eluted from the resin with rheb storage buffer containing 50 mg/ml Flag peptide and stored on ice until use. In the experiments using PRAS40 phosphorylated by Akt/PKB, Flag-PRAS40 still bound to the Flag-antibody resin was incubated for 30 min at 30 C in mTORC1 kinase assay buffer containing 400 ng of T308D Akt/PKB in the presence or absence of 500 mM ATP. The resin-bound Flag-PRAS40 was then washed three times with mTORC1 kinase assay buffer and eluted as above and stored on ice until use.
Mass Spectrometric Analysis mTOR and raptor immunoprecipitates prepared from 30 million HEK293E cells were resolved by SDS-PAGE, and the Coomassiestained 40 kDa band corresponding to PRAS40 was excised and digested with trypsin overnight. The resulting peptides were separated by liquid chromatography (NanoAcquity UPLC, Waters) using a selfpacked Jupiter 3 micron C18 column. The eluting peptides were mass analyzed prior to collisionally induced dissociation (CID) using a ThermoFisher LTQ linear ion trap mass spectrometer equipped with a nanospray source. Selected mass values from the MS/MS spectra were used to search the human segment of the National Center for Biotechnology Information (NCBI) nonredundant protein database using Xcalibur Mass Spectrometry software (Thermo Fischer Scientific). Depending on the purification, two to six distinct PRAS40-derived peptides were identified.
Cell Size Determinations
To measure cell size, cells were grown to confluence in 6 cm culture dishes, harvested, diluted 1:10, and replated into fresh media. Twelve hours later, the cells were harvested by trypsinization in a 1 ml volume, diluted 1:20 with counting solution (Isoton II Diluent, Beckman Coulter), and cell diameters and volumes determined using a particle size counter (Coulter Z2, Beckman Coulter) with Coulter Z2 AccuComp software.
cDNA Manipulations, Mutagenesis, and Sequence Alignments as well as Drosophila and Mammalian RNAi and Analysis See the Supplemental Experimental Procedures.
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